Riferimento:
J Nucl Med. 2011 Jun;52(6):841-4.
Autori:
Maecke HR, Reubi JC.
Fonte:
J Nucl Med. 2011 Jun;52(6):841-4.
Anno:
2011
Azione:
Radiopeptidi a base di somatostatina hanno un reale impatto diagnostico-terapeutico.
Target:
Radiopeptidi-somatostatina/bersagli nella medicina nucleare.
ABSTRACT
Radiolabeled peptides have been an important class of compounds in radiopharmaceutical sciences and nuclear medicine for more than 20 years. Despite strong research efforts, only somatostatin-based radiopeptides have a real impact on patient care, diagnostically and therapeutically. [(111)In-diethylenetriaminepentaacetic acid(0)]octreotide is commercially available for imaging. Imaging was highly improved by the introduction of PET radionuclides such as (68)Ga, (64)Cu, and (18)F. Two peptides are successfully used in targeted radionuclide therapy when bound to DOTA and labeled with (90)Y and (177)Lu.
Free full text
Sostanze:
